
  
    
      
        
        Tyrosine_NNP kinases_NNS regulate_VB signaling_VBG pathways_NNS that_WDT control_NN cell_NN growth_NN ,_, proliferation_NN ,_,
        motility_NN ,_, and_CC other_JJ critical_JJ cellular_JJ processes_NNS ._. Mutations_NNP in_IN tyrosine_NN kinase_NN genes_NNS can_MD
        lead_VB to_TO abnormal_JJ kinase_NN activity_NN ,_, and_CC some_DT tumors_NNS become_VBP dependent_JJ upon_IN this_DT activity_NN for_IN
        growth_NN and_CC survival_NN ._. Thus_RB ,_, kinases_NNS are_VBP attractive_JJ targets_NNS for_IN anti-cancer_JJ drugs_NNS ._. Examples_NNS
        of_IN new_JJ kinase_NN inhibitors_NNS include_VBP gefitinib_NN and_CC erlotinib_NN ,_, which_WDT have_VBP recently_RB shown_VBN promise_NN
        in_IN treating_VBG non-small-cell_JJ lung_NN cancer_NN ._. Unfortunately_RB ,_, gefitinib_NN and_CC erlotinib_NN work_NN only_RB in_IN
        a_DT subset_NN of_IN patients_NNS ,_, and_CC they_PRP can_MD have_VB severe_JJ side_NN effects_NNS ,_, albeit_IN infrequently_RB ._. So_RB
        researchers_NNS have_VBP been_VBN trying_VBG to_TO find_VB ways_NNS to_TO predict_VB who_WP will_MD benefit_VB from_IN therapy_NN with_IN
        these_DT drugs_NNS and_CC who_WP wo_MD n't_RB ._.
        Following_VBG the_DT work_NN of_IN Lynch_NNP et_CC al_NN ._. (_( N_NNP Engl_NNP J_NNP Med_NNP 350_CD :_: 2129_CD –_NN 2139_CD )_) and_CC Paez_NNP et_CC al_NN ._.
        (_( Science_NNP 304_CD :_: 1497_CD –_NN 1500_CD )_) ,_, William_NNP Pao_NNP and_CC colleagues_NNS have_VBP previously_RB shown_VBN that_IN the_DT
        epidermal_NN growth_NN factor_NN receptor_NN (_( EGFR_NNP )_) ,_, a_DT tyrosine_NN kinase_NN ,_, is_VBZ often_RB mutated_VBN in_IN
        non-small-cell_JJ lung_NN cancers_NNS ,_, and_CC that_IN tumors_NNS that_WDT harbor_NN such_JJ mutations_NNS are_VBP sensitive_JJ to_TO
        gefitinib_NN and_CC erlotinib_NN ._.
        In_IN this_DT new_JJ study_NN ,_, they_PRP focused_VBD on_IN a_DT signaling_VBG protein_NN called_VBN KRAS_NNP ,_, which_WDT functions_NNS
        downstream_JJ of_IN many_JJ tyrosine_NN kinases_NNS ,_, including_VBG EGFR_NNP ._. The_DT KRAS_NNP gene_NN is_VBZ also_RB often_RB mutated_VBN in_IN
        lung_NN cancers_NNS ,_, but_CC very_RB few_JJ cancers_NNS have_VBP mutations_NNS in_IN both_DT EGFR_NNP and_CC the_DT KRAS_NNP gene_NN ._. To_TO find_VB
        out_IN whether_IN KRAS_NNP mutations_NNS could_MD help_VB to_TO predict_VB which_WDT patients_NNS would_MD respond_VB to_TO gefitinib_NN
        or_CC erlotinib_NN ,_, the_DT researchers_NNS looked_VBD for_IN mutations_NNS in_IN EGFR_NNP and_CC KRAS_NNP genes_NNS in_IN 60_CD tumors_NNS for_IN
        which_WDT sensitivity_NN to_TO either_CC drug_NN was_VBD known_VBN ._.
        They_PRP extended_VBD their_PRP$ earlier_JJR findings_NNS that_IN EGFR_NNP mutations_NNS (_( which_WDT were_VBD found_VBN in_IN 17_CD of_IN the_DT
        tumors_NNS )_) were_VBD associated_VBN with_IN sensitivity_NN to_TO the_DT kinase_NN inhibitors_NNS ,_, and_CC found_VBD that_IN tumors_NNS
        that_WDT had_VBD mutations_NNS in_IN KRAS_NNP (_( a_DT total_NN of_IN nine_CD )_) were_VBD refractory_JJ (_( i_NNP ._. e_SYM ._. ,_, did_VBD not_RB respond_VB )_) to_TO
        either_CC drug_NN ._.
        These_DT results_NNS need_VBP to_TO be_VB validated_JJ in_IN larger_JJR and_CC prospective_JJ trials_NNS that_WDT use_NN
        standardized_JJ mutation_NN detection_NN techniques_NNS ._. If_IN they_PRP are_VBP confirmed_VBN ,_, knowing_VBG the_DT mutation_NN
        status_NN of_IN EGFR_NNP and_CC KRAS_NNP in_IN tumors_NNS could_MD help_VB physicians_NNS decide_VB which_WDT patients_NNS should_MD
        receive_VB gefitinib_NN and_CC /_NN or_CC erlotinib_NN ._. As_IN Inoue_NNP and_CC Nukiwa_NNP state_NN in_IN a_DT Perspective_NNP that_WDT
        accompanies_VBZ the_DT article_NN ,_, “ By_IN combining_VBG all_PDT the_DT factors_NNS that_WDT relate_VBP to_TO response_NN or_CC
        resistance_NN ,_, patients_NNS who_WP will_MD benefit_VB from_IN treatment_NN can_MD hopefully_RB be_VB identified_VBN ._.
        Undoubtedly_NNP we_PRP have_VBP taken_VBN a_DT great_JJ step_NN forward_RB in_IN molecular_JJ therapy_NN for_IN lung_NN cancer_NN
        treatment_NN ._.”
      
    
  
